Eleni Taoula’s Post

𝐇𝐞𝐚𝐝 𝐚𝐧𝐝 𝐍𝐞𝐜𝐤 𝐂𝐚𝐧𝐜𝐞𝐫: 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐑𝐢𝐬𝐤𝐬 𝐚𝐧𝐝 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐃𝐞𝐦𝐨 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐄𝐱𝐜𝐞𝐥 𝐏𝐢𝐯𝐨𝐭 𝐚𝐧𝐝 𝐓𝐨𝐂: https://lnkd.in/d92M2bWt 🔷 The #HeadandNeckCancer Market Size is estimated to grow at a CAGR of 8.0 % during the forecast period for 2024-2031. 🔷 According to the study published in NCBI (2014), head and neck cancer (HNC) is the sixth most common cancer worldwide, with an estimated 630,000 new cases every year. Specifically, this type of cancer includes tumors of the oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity. Tobacco and alcohol consumption is strongly associated with head and neck cancer. ▪ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐈𝐧 𝐓𝐡𝐞 𝐇𝐞𝐚𝐝 𝐚𝐧𝐝 𝐍𝐞𝐜𝐤 𝐂𝐚𝐧𝐜𝐞𝐫 : ▪ Advaxis Pharmaceuticals. ▪ Amgen Inc. ▪ AstraZeneca ▪ Boehringer Ingelheim ▪ Bristol-Myers Squibb Pharma Company ▪ CEL-SCI Corporation ▪ GlaxoSmithKline Consumer Healthcare, L.P. ▪ Incyte ▪ iRx Clinical Pharmacy ▪ MacroGenics, Inc. ▪ Merck KGaA, Darmstadt, Germany ▪ Novartis ▪ PFIZER INC. ▪ Roche ▪ Viracta Therapeutics, Inc. #HeadAndNeckCancer #CancerResearch #Oncology #HealthcareInnovation #CancerTreatment #PublicHealth 

Global Non-Small Cell Lung Cancer Market Size, Share & Trends Analysis Report By cancer type (metastatic lung cancer, pulmonary neuroendocrine tumours, mediastina tumours, non-small cell lung cancer, mesothelioma andchest wall tumours.) By molecule type (small molecules, biologics.By Drug class (antimetabolites, EGFR inhibitors, mitotic inhibitors, alkylating agents, multi-kinase inhibitors andothers.) By treatment type (radiation therapy, targeted therapy, chemotherapy, immunotherapy) By therapy type, (single drug therapy andcombination therapy.) By end user (hospitals, homecare, speciality clinics andothers) By distribution channel, (direct hospital pharmacy, retail pharmacy, online andothers), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031. 🌐𝐈𝐌𝐈𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐯𝐭. 𝐋𝐭𝐝. 𝐆𝐞𝐭 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/d9qPgWXQ 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭: AbbVie Agena Bioscience AGENNIX AG Alimtas Bioventures Allergan Amgen ArQule U.K. Ltd a Co Astellas Pharma AstraZeneca Avastin CH Avid Bioservices Bayer Biocept, Inc. Biodesix, Inc. Biogen Black Diamond Therapeutics Blueprint Medicines Boehringer Ingelheim Bristol Myers Squibb Celgene Daiichi Sankyo US Eisai Co., Ltd. Eli Lilly and Company Exosome Diagnostics F. Hoffmann-La Roche Ltd Genentech. GSK Illumina Merck Group Novartis Novocure Oryzon Genomics SA Panduit Pfizer QIAGEN #lungcancer #cancer #breastcancer #lungcancerawareness #cancerawareness #prostatecancer #cancersucks #pancreaticcancer #coloncancer #health #cancersurvivor #ovariancancer #braincancer #oncology #livercancer #cancertreatment #leukemia #chemo #chemotherapy #cancerfighter #skincancer #cervicalcancer #cancerfree #cancerresearch #lungcancerawarenessmonth #testicularcancer #thyroidcancer #stomachcancer #lungcancerresearch #lungcancersurvivor

𝐁𝐢𝐨-𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫: 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐆𝐫𝐚𝐧𝐮𝐥𝐚𝐫 𝐁𝐢𝐨𝐜𝐡𝐚𝐫 𝐚𝐧𝐝 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 ✅𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲- https://lnkd.in/gicj59-H (𝙘𝙤𝙧𝙥𝙤𝙧𝙖𝙩𝙚 𝙢𝙖𝙞𝙡 𝙄𝘿 𝙥𝙧𝙚𝙛𝙚𝙧𝙧𝙚𝙙 𝙛𝙤𝙧 𝙩𝙤𝙥 𝙥𝙧𝙞𝙤𝙧𝙞𝙩𝙮) T-cell therapy is a type of immunotherapy that fights cancer by using specifically engineered T cells, which are part of the immune system. T cells from a patient’s blood are taken and manipulated to develop specific structures on their surface known as chimeric antigen receptors. The new receptors on these T cells enable them to latch onto a specific antigen on the patient’s tumor cells and destroy them when they are reinfused into the patient. ✅𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐦𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐚𝐬 𝐛𝐞𝐥𝐨𝐰: Amgen (US) bluebird bio Inc. (US) Fate Therapeutics Inc. (US) ⭕Gilead Sciences Inc. (US) ⭕Merck KGaA Pharmaceutical (Germany) ⭕Novartis (Switzerland) ⭕Pfizer Inc. (US) ⭕Sorrento Therapeutics, Inc. Therapeutics (US) ⭕TCR² Therapeutics (US) ⭕TScan Therapeutics, Inc. (US) #Immunotherapy #CancerTreatment #CellTherapy #PrecisionMedicine #CAR-TCellTherapy #Immunooncology #TCellEngagement #CellularImmunotherapy #InnovativeTherapeutics #PersonalizedMedicine #gis #analysis #demand #growth #like #repost

𝐂𝐚𝐧𝐝𝐢𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐰𝐢𝐭𝐡 $𝟑𝟕𝟎𝐌 𝐭𝐨 𝐋𝐞𝐚𝐝 𝐢𝐧 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Candid Therapeutics, Inc. ("Candid") Candid Therapeutics, a biotechnology company focused on developing transformative drugs for autoimmune diseases, has officially launched. With groundbreaking data showing the crucial role of B lymphocytes in autoimmune pathology, Candid is pioneering T-cell engager (TCE) antibodies to selectively deplete B cell populations. Candid aims to lead the market in TCE therapies for conditions like rheumatoid arthritis and myasthenia gravis. To accelerate development, Candid acquired Vignette Bio and TRC 2004 in a three-way merger. This acquisition brings two cutting-edge bispecific TCEs: CND106 (BCMAxCD3 bispecific antibody) and CND261 (CD20xCD3 bispecific antibody), both with potential to become best-in-class autoimmune therapies. These candidates have completed Phase 1 studies, with promising data from over 130 oncology patients. The Candid team includes Ken Song, MD (CEO) Ken Song, Timothy Lu, MD, PhD (CSO), Bernie Huyghe, PhD (CTO) Bernie Huyghe, and Arvind Kush (CFO) Arvind Kush. Candid has raised over $370 million from top-tier investors, including Venrock Healthcare Capital Partners, Fairmount, TCGX, venBio Partners, and others, underscoring confidence in its vision to advance TCE therapies for autoimmune diseases. “TCE antibodies hold the potential to revolutionize autoimmune treatments," said Ken Song, MD Ken Song, CEO of Candid Therapeutics. "We aim to surpass the success of therapies like Humira® and Rituxan®, creating a new paradigm for autoimmune disease treatment.” #Biotechnology #AutoimmuneDisease #CellTherapy #TCEAntibodies #LifeSciences #PharmaInnovation #Healthcare #Biopharma #MedicalResearch #GeneticMedicine

The global #CAR #T-#Cell #Therapy #Market is projected to skyrocket to over 𝐔𝐒𝐃 𝟐𝟐.𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, up from 𝐔𝐒𝐃 𝟐.𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑. This represents an impressive #CAGR of 30% from 2024 to 2032. This remarkable growth highlights the increasing importance of innovative cancer treatments. 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐭𝐨 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐯𝐢𝐬𝐢𝐭:- https://lnkd.in/gZmTCPCm 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 Novartis bluebird bio. Cellectis Bristol Myers Squibb Merck. Juno Therapeutics, Inc. Celyad Oncology Celgene Sorrento Therapeutics, Inc. Miltenyi Biotec Intellia Therapeutics, Inc. Pfizer, Inc. Autolus Therapeutics Gilead Sciences, Cartesian Therapeutics, Caribou Biosciences, Inc. Other Prominent Players #CARTCellTherapy #Biotech #HealthcareInnovation #MarketGrowth #CancerTreatment

𝗪𝗵𝗶𝗰𝗵 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗱𝗼 𝘆𝗼𝘂 𝘁𝗵𝗶𝗻𝗸 𝗶𝘀 𝗯𝗲𝘀𝘁 𝘄𝗵𝗲𝗻 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗶𝗻𝗴 𝗮𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝘁𝗮𝗿𝗴𝗲𝘁? 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 provide high specificity and affinity, long half-life, and highly targeted cytotoxicity. Additionally, they leverage established manufacturing and regulatory pathways, ensuring a streamlined progression from development to clinical application. 𝗣𝗲𝗽𝘁𝗶𝗱𝗲𝘀 not only offer remarkable penetrability and the potential for oral dosing but also benefit from rapid synthesis and modification capabilities, accelerating the discovery process and allowing for quick iteration and optimization. At IRBM, our extensive expertise in 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗽𝗵𝗮𝘀𝗲 positions us as a leading partner within the field. With a proven track record of 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗻𝗴 𝘁𝗼 𝗮𝗻 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗿𝘂𝗴, as well as the development of our own internal 𝗖𝗥𝗟𝗙𝟮 𝗔𝗗𝗖 𝗮𝘀𝘀𝗲𝘁, we offer unparalleled experience and innovation. Our 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝗴𝗿𝗼𝘂𝗽 is also highly regarded for its unmatched capabilities, providing 𝘁𝗮𝗶𝗹𝗼𝗿𝗲𝗱 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗺𝗲𝗲𝘁 𝘁𝗵𝗲 𝘂𝗻𝗶𝗾𝘂𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗼𝗳 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. Which is your preferred modality? ▶️ 𝗣𝗹𝗮𝘆 𝗮𝗹𝗼𝗻𝗴 by simply typing "Peptide" or "Antibody" in the comments below! #oncologyresearch #cancertherapy #drugdiscovery #irbm

Thoughts on this? >> Candel’s promising Phase 2 data in pancreatic cancer; Microbiome biotech raises £27M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #healthcare #pharma #biotech

What a promising $1.5 billion deal between Eisai and SEED! This strategic partnership's purpose is to develop a new generation of drugs, called molecular glue degraders (MGDs), which recruit disease-causing proteins for rapid destruction and aim at previously untreated neurodegeneration and oncology targets. These MGDs are a novel and groundbreaking therapeutic method in drug discovery, primarily working via the ubiquitin-proteasome pathway, by focusing on tightening and simplifying the connection of an E3 ligase with a disease-causing protein for ubiquitination and subsequent degradation. Hopefully, with further advancements in this field, Eisai and SEED will be able to meet the needs of many patients worldwide suffering from previously untreated diseases.

Osimertinib is classified as a third-generation EGFR tyrosine kinase inhibitor (TKI) used for the treatment of non-small cell lung cancer (NSCLC).  Pharmaffiliates feel proud to support you in your latest drug discovery and development projects related to Osimertinib- novel third-generation EGFR tyrosine kinase inhibitor. 𝐓𝐨 𝐯𝐢𝐞𝐰 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐥𝐢𝐬𝐭 𝐨𝐟 𝐎𝐬𝐢𝐦𝐞𝐫𝐭𝐢𝐧𝐢𝐛 𝐢𝐦𝐩𝐮𝐫𝐢𝐭𝐢𝐞𝐬, 𝐀𝐏𝐈 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 & 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐬 - https://lnkd.in/gckRv5P4 #research #ReferenceStandards #Pharmaffiliates #AnalyticalChemistry #DrugDiscovery #drugresearch #Impurities #contractresearch #cro #cdmo #stableisotopes #intermediates #pharmaceutical #research #researchanddevelopment #analyticalchemistry #drugdevelopment #qualitycontrol #qc #drugdiscovery #pharmacokinetic #CMC #CDMO #impurityqualification #Pharmacodynamics #drugmanufacturing #healthcareinnovation #pharmamanufacturing #api #activepharmaceuticalingredient #Osimertinib

Thoughts on this? >> Candel’s promising Phase 2 data in pancreatic cancer; Microbiome biotech raises £27M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #healthcare #biotech #pharma